Summit partners with AstraZeneca and Daiichi Sankyo on ivonescimab

• Summit Therapeutics (NASDAQ:SMMT) signed a clinical trial collaboration with AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo to test ivonescimab with Datroway across multiple solid tumors.
• The companies plan to begin with a Phase 3 trial in first-line triple-negative breast cancer.
• Each company will provide its respective therapy and share trial costs while retaining development and commercial rights to its own medicine.

Summit Therapeutics (NASDAQ:SMMT) announced a clinical trial collaboration with AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo to evaluate ivonescimab with Datroway in multiple solid tumor settings, including breast and lung cancer.

The companies intend to begin the collaboration with a Phase 3 study in first-line triple-negative breast cancer, expanding Summit’s ivonescimab development program into breast cancer.

“We believe this collaboration with Daiichi Sankyo and AstraZeneca reflects increasing conviction in ivonescimab’s potential as a foundational next-generation immunotherapy,” said Summit Therapeutics President and Co-Chief Executive Officer Maky Zanganeh, Ph.D.

Under the agreement, Summit, AstraZeneca and Daiichi Sankyo will each contribute their respective therapies and share trial costs, while the planned studies will be sponsored by AstraZeneca or Daiichi Sankyo.

Ivonescimab is an investigational PD-1/VEGF bispecific antibody, while Datroway is a TROP2-directed antibody-drug conjugate discovered by Daiichi Sankyo and jointly developed and commercialized with AstraZeneca.

Summit, AstraZeneca and Daiichi Sankyo will retain development and commercial rights to their respective medicines, with the collaboration intended to evaluate the combination across additional solid tumor settings beyond triple-negative breast cancer.

SEO Metadata Section

Slug:

Meta Title:

FAQ Section

1. What collaboration did Summit Therapeutics announce?

Summit Therapeutics (NASDAQ:SMMT) signed a clinical trial collaboration with AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo to evaluate ivonescimab combined with Datroway across multiple solid tumors.

2. What cancer will the first combination trial evaluate?

Summit Therapeutics (NASDAQ:SMMT) and AstraZeneca (NASDAQ:AZN) plan to begin with a Phase 3 trial evaluating ivonescimab plus Datroway in first-line triple-negative breast cancer.

3. What is ivonescimab?

Summit Therapeutics (NASDAQ:SMMT) is developing ivonescimab as an investigational bispecific antibody designed to target both PD-1 and VEGF pathways.

4. What is Datroway?

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo are jointly developing and commercializing Datroway, a TROP2-directed antibody-drug conjugate based on Daiichi Sankyo’s DXd technology.

5. How will the companies share responsibilities for the trials?

Summit Therapeutics (NASDAQ:SMMT), AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo will each provide their respective therapies and contribute to trial costs while retaining rights to their own medicines.